Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Louisiana health officials have confirmed a rare infection caused by Naegleria fowleri, commonly called the “brain-eating amoeba,” in a resident who most likely contracted the infection after swimming in Lake Claiborne in Louisiana.

The Louisiana Department of Health confirmed the case this week, issuing a warning to people entering warm freshwater. It is the fourth documented Naegleria fowleri infection in Louisiana since 1937.

The case comes as health officials continue to warn about the seasonal risk of the amoeba, which thrives in warm freshwater, particularly during the summer months. According to CDC data, most US cases occur in July and August.

The Amoeba Enters Through The Nose

From the nasal pathway, the organism can travel along the olfactory nerves into the brain and cause primary amebic meningoencephalitis (PAM), an infection that progresses rapidly and causes inflammation and destruction of brain tissue.

Swallowing contaminated water also does not cause Naegleria infection, and the infection cannot spread from one person to another.

Also read: Fournier Gangrene: Woman Develops Rare Flesh-eating Infection After Bikini Shave, Herbal Application

Louisiana Health Officials Warn People

Naegleria fowleri is naturally found in warm freshwater lakes, ponds and rivers, as well as some hot springs and other warm-water environments.

According to CIDRAP, the amoeba can survive at temperatures as high as about 115°F (46°C). Cases are particularly linked with freshwater exposure during periods of high temperatures.

The risk remains extremely low despite its potentially devastating outcome. The CDC recorded 180 PAM cases in the US from 1937 through 2025, with cases ranging from zero to eight per year.

The LDH said recreational water users should not assume that warm freshwater is completely risk-free. “Though the risk of infection is low, recreational water users should always assume there is a risk when they enter warm fresh water.”

The department added that people can reduce their risk by preventing water from entering your enters the nose. That can include using nose clips or keeping the nose above water when swimming in warm freshwater.

Also read: Can You Contract Deadly Flesh-Eating Bacteria At The Beach? Louisiana Health Officials Warn Beachgoers

Symptoms Can Mimic Meningitis

Primary amebic meningoencephalitis can initially mimic other infections. Early symptoms can include headache, fever, nausea and vomiting. As the infection progresses, patients can develop a stiff neck, confusion, problems with balance, seizures, hallucinations and loss of consciousness.

The illness progresses extremely quickly, with CDC data indicating that symptoms generally begin within 1 to 12 days after exposure. Death can occur within days after symptoms appear. As the disease is extremely rare and its early symptoms resemble other forms of meningitis, diagnosis can be challenging.

The Louisiana case follows another recent case in the state involving an 8-year-old Ruston girl, who was hospitalized after developing a Naegleria fowleri infection that health officials said may have been acquired while swimming in a North Louisiana lake.

Simple Precautions Can Reduce Exposure

The cases highlight the importance of taking precautions around warm freshwater during the summer, even though the overall probability of infection remains extremely small.

The CDC recommends avoiding activities in warm freshwater when possible, particularly during periods of high water temperatures. People who do enter such water can reduce exposure by using nose clips or keeping their head above water, and by avoiding stirring up sediment in shallow, warm areas.

Another important precaution concerns nasal rinsing. Naegleria can also be transmitted when contaminated tap water is used in devices such as neti pots. For nasal rinsing, the CDC recommends using distilled or sterile water, or water that has been boiled and cooled.

Amid an ongoing Salmonella outbreak that has infected hundreds of people, vulnerable groups in the UK are being advised to avoid undercooked or runny eggs.

The Food Standards Agency (FSA) issued the precautionary advice after the UK Health Security Agency (UKHSA) declared a national outbreak. The outbreak has infected 207 people across the UK, with one death and 34 hospitalisations.

Officials suspect imported eggs or food products containing imported eggs may be behind the outbreak.

However, the FSA said well-cooked eggs served in restaurants, cafes and takeaways are safe to eat.

Who Is at Risk?

The FSA advised vulnerable groups, including:

• Children under five
• Adults over 65
• Pregnant women
• People with certain health conditions or weakened immune systems

Ian Young, chief scientific adviser at the FSA, said vulnerable people eating out should ensure that eggs and egg products are thoroughly cooked.

Which Foods Should Be Avoided?

The FSA advised vulnerable people to avoid runny eggs and freshly made foods that may contain uncooked eggs, including:

• Mayonnaise
• Soufflés
• Hollandaise sauce

Are Supermarket Eggs Safe?

Young reiterated that people can continue to buy British eggs from supermarkets. Chickens bred in the UK are vaccinated against common strains of Salmonella.

“There is no link to those eggs to this current outbreak,” he said.

He described the outbreak as “unusually large and rapidly increasing” and urged people to take precautions.

The UKHSA has launched an investigation to identify the source of the outbreak. Initial findings suggest it may be linked to eggs imported from outside the UK, although the source has not yet been definitively established.

Dr Kathleen O'Reilly, associate professor at the London School of Hygiene & Tropical Medicine, said the investigation involves identifying additional cases and examining possible common sources of infection.

Where Have Cases Been Reported?

Cases have been reported across the UK:

• England: 199 cases
• Scotland: 6 cases
• Wales: 1 case
• Northern Ireland: 1 case

In England, London has reported the highest number of cases, with 47, followed by Yorkshire and the Humber with 38.

What Is Salmonella?

Salmonella is a bacterial infection that commonly causes diarrhoea and gastrointestinal illness.

Common symptoms include:

• Diarrhoea
• Stomach cramps
• Vomiting
• Fever

How Does Salmonella Spread?

The UKHSA stated that Salmonella Enteritidis is the most common Salmonella serovar in England and a leading cause of salmonellosis.

Like other non-typhoidal Salmonella infections, it can spread through contaminated food, including:

• Eggs
• Poultry
• Meat
• Unpasteurised dairy products
• Fresh produce

The bacteria can also spread through contact with contaminated environments or from person to person.

How to Reduce the Risk of Salmonella

Dr O'Reilly advised people to fully cook eggs before eating them and maintain good food hygiene.

Key precautions include:

• Cook eggs thoroughly, including omelettes, rather than leaving them runny.
• Wash your hands with soap after handling food and during food preparation.
• Clean chopping boards and utensils after preparing food.
• Check food hygiene ratings when choosing catering outlets.

People who develop diarrhoea or stomach cramps should rest and drink plenty of fluids. Young children, older adults and other vulnerable people who become ill should seek medical advice.

Moderna and Merck’s personalized mRNA cancer vaccine has shown statistically significant and clinically meaningful improvements. The late-stage trial showed recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) when combined with Keytruda in patients with melanoma, an aggressive form of skin cancer.

The vaccine, intismeran autogene (mRNA-4157/V940), is custom-made for each patient based on the unique genetic characteristics of their tumor. It is designed to work alongside Keytruda (pembrolizumab), an immunotherapy that helps the immune system attack cancer cells.

What Makes the Vaccine Different?

According to experts, the development moves personalized cancer therapy closer to a practical clinical reality.

“A tumor-specific mRNA vaccine offers a way of making the immune response more targeted by using the individual tumor’s molecular characteristics to identify the abnormal signals that the immune system should recognize,” Prof. Jyoti Bajpai, Director – Medical Precision Immuno-Oncology, Apollo Hospitals, Mumbai, told HealthandMe.

What Did the Phase 3 Trial Find?

In the Phase 3 INTerpath-001 trial, the combination met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS).

Compared with Keytruda alone, the combination of intismeran autogene and Keytruda showed statistically significant and clinically meaningful improvements in both RFS and DMFS.

The findings were reported in patients with stage IIB, IIC, III, or IV cutaneous melanoma who had undergone complete surgical removal of their cancer and had not previously received systemic therapy.

The mRNA Vaccine: How It Works

After tumor sequencing, up to ~34 patient-specific neoantigens are encoded into a single mRNA construct delivered in lipid nanoparticles.

Host cells translate the neoantigens, which are then presented on MHC, driving de novo and expanded neoantigen-specific CD8+ and CD4+ T-cell responses.

When combined with PD-1 blockade, the vaccine supplies the antigenic “signal” while the checkpoint inhibitor supplies the “permission” to attack.

“The result is a more focused, polyclonal, and potentially longer-lived anti-tumor immune response—exactly what is needed to clear residual microscopic disease after resection,” Dr. Shyam Aggarwal, Chairman, Medical Oncology, Sir Ganga Ram Hospital, told HealthandMe.

Early translational data from KEYNOTE-942 already showed durable neoantigen-specific T-cell responses, supporting the idea that the vaccine can generate immune memory that outlasts the treatment period.

“Immunotherapy releases the body’s natural brakes to attack cancer, whereas the custom vaccine acts like a precision GPS—training the immune system to recognize the unique genetic signature of that patient's specific tumour. Immunotherapy mobilizes the immune response, but the vaccine tells it exactly where to go,” Prof. Jyoti said.

What Could It Mean for Cancer Treatment?

“The practical implication is a shift in the adjuvant paradigm: rather than relying solely on broad immune checkpoint inhibition or chemotherapy, we can now envision adding a tumor-specific ‘instruction set’ that educates the patient’s own T-cell repertoire against the unique mutational fingerprint of their cancer,” the noted oncologist said.

He added that the manufacturing turnaround, currently ~6 weeks from biopsy to first dose, remains a logistical and cost challenge. However, the COVID-era mRNA infrastructure has shown that rapid, decentralized production of custom constructs is feasible.

mRNA’s Potential For India

India’s cancer burden has continued to rise steadily over the past five years, with the estimated number of new cancer cases increasing from 14.26 lakh in 2021 to 15.70 lakh in 2025, while annual cancer-related deaths also climbed from 7.89 lakh to an estimated 8.69 lakh during the same period, according to data placed before Parliament recently.

For India, this technology has intriguing potential, Dr Jyoti said.

While typical skin melanoma is less common here, India sees higher rates of acral and mucosal subtypes, which tend to be aggressive and diagnosed late.

“A tailored neoantigen approach could be very useful for these complex cases. However, manufacturing costs, long turnaround times for genomic sequencing, and cold-chain logistics mean translating this into routine clinical care in India may take time,” she added.